Related Experiment Videos
Limbic-frontal circuitry in major depression: a path modeling metanalysis.
D A Seminowicz1, H S Mayberg, A R McIntosh
1Rotman Research Institute, Baycrest Centre for Geriatric Care, 3560 Bathurst Street, Toronto, Ontario, Canada M6A 2E1.
Neuroimage
|April 28, 2004
Summary
This meta-analysis reveals distinct neural pathway differences in major depression (MDD) based on treatment response. Identifying these brain connectivity patterns can help personalize depression treatment selection.
Area of Science:
- Neuroscience
- Psychiatry
- Medical Imaging
Background:
- Major Depressive Disorder (MDD) is characterized by complex limbic-cortical dysfunction.
- Previous research suggests variability in neural pathways contributes to MDD heterogeneity.
- Understanding effective connectivity is crucial for characterizing the MDD neural systems level.
Purpose of the Study:
- To conduct a meta-analysis of effective connectivity in MDD using FDG PET data.
- To test theories of limbic-cortical dysfunction in MDD using a formal depression model.
- To identify neural pathway differences associated with treatment response in MDD.
Main Methods:
- A meta-analysis of FDG PET data from 119 MDD patients and 42 controls across three studies.
- Structural Equation Modeling (SEM) was used to create and test a 7-region depression model.
- The model included lateral prefrontal cortex, anterior thalamus, cingulate cortex, orbital frontal cortex, and hippocampus.
Main Results:
- A stable 7-region depression model was identified across patient groups.
- Limbic-cortical pathways differentiated drug treatment responders from non-responders.
- Non-responders showed additional limbic-subcortical pathway abnormalities; treatment type (pharmacotherapy vs. CBT) also correlated with specific pathway differences.
Conclusions:
- Effective connectivity models offer a systems-level characterization of the MDD phenotype.
- Neural pathway differences are linked to treatment response variability in MDD.
- These findings have implications for developing brain-based algorithms for personalized depression treatment selection.